Mike Grey has served as chairman of the board since January 2020. Previously he served as executive chairman since March 2019. Mike is a co-founder of Mirum.

Mike previously served as chief executive officer from the company’s inception in May 2018 to March 2019. Mr. Grey has served as executive chairman of Plexium, Inc. since January 2021; Reneo Pharmaceuticals, Inc. since December 2017; and Spruce Biosciences, Inc, since April 2017. He has also served as a venture partner at Pappas Ventures since January 2010 and as president and chief executive officer of Curzion Pharmaceuticals, Inc. Mike served from October 2015 to January 2017 as the president and chief executive officer of Amplyx and from September 2014 to December 2017 as chairman and chief executive officer of Reneo. From February 2011 to June 2014, Mike served as president and chief executive officer of Lumena, which was acquired by Shire plc in June 2014. Mike has 40 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and president of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as vice president, corporate development and director of international licensing. Mr. Grey also serves on the board of directors of Horizon Therapeutics plc.

Mike received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.

Saira Ramasastry has served as a member of our board of directors since June 2022. Ms. Ramasastry is the managing partner of Life Sciences Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies. Prior to founding Life Sciences Advisory, Ms. Ramasastry spent 10 years as an investment banker with Merrill Lynch & Company, where she helped establish the biotechnology practice and advised on mergers and acquisitions, and strategic and capital markets transactions. Previously, she served as a financial analyst in mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the board of directors for DayOne Biopharmaceuticals, Inc., Vir Biotechnology Inc., Akouos, Inc., and Glenmark Pharmaceuticals Ltd. She is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Ms. Ramasastry holds a B.A. in economics and an M.S. in management science and engineering with honors and distinction from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge.